Eur Rev Med Pharmacol Sci 2017; 21 (2 Suppl): 15-29

Natural molecules for the therapy of hyperandrogenism and metabolic disorders in PCOS

V. Cappelli, M.C. Musacchio, A. Bulfoni, G. Morgante, V. De Leo

Department of Molecular Medicine and Development, University of Siena, Siena, Italy. vincenzo.deleo@unisi.it


OBJECTIVE: Polycystic ovary syndrome (PCOS) is the most common endocrinopathy of women of reproductive age and a complex endocrine condition, due to its heterogeneity and uncertainty about its etiology. However, PCOS is also associated with other metabolic abnormalities such as insulin resistance, impaired glucose tolerance, and diabetes. There are few medications that are approved for the most common symptoms of PCOS, leading to the off-label use of medications that were approved for other indications. One of the most common medications being used off label for PCOS is metformin.

Research of other effective therapeutic options has included the utility of inositol.

PATIENTS AND METHODS: A systematic literature search of PubMed was performed using the following combination of terms: ‘PCOS’, ‘hyperandrogenism’ ‘inositol’, ‘natural molecules’. Only papers published between 2000 and 2016 were included in our analysis. The present review analyzes all aspects of the choice of natural molecules in the treatment of hyperandrogenism and metabolic disorders in PCOS women.

RESULTS: The rationale underlying the use of inositols as a therapeutic application in PCOS derives from their activities as insulin mimetic agents and their salutary effects on metabolism and hyperandrogenism without side effects.

CONCLUSIONS: In this review will discuss the role of a number of natural associations between inositol and different substances in the treatment of hyperandrogenic symptoms in PCOS women.

Published on: 2017/07/06


Free PDF Download

To cite this article

V. Cappelli, M.C. Musacchio, A. Bulfoni, G. Morgante, V. De Leo
Natural molecules for the therapy of hyperandrogenism and metabolic disorders in PCOS

Eur Rev Med Pharmacol Sci
Year: 2017
Vol. 21 - N. 2 Suppl
Pages: 15-29